Free Trial

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Leerink Partners

Rhythm Pharmaceuticals logo with Medical background

Research analysts at Leerink Partners started coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) in a report released on Monday, Marketbeat Ratings reports. The firm set an "outperform" rating and a $88.00 price target on the stock. Leerink Partners' price target points to a potential upside of 32.55% from the company's previous close.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Wells Fargo & Company lifted their target price on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a report on Monday, April 7th. Needham & Company LLC lifted their target price on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, May 7th. Canaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Finally, Stifel Nicolaus lifted their target price on shares of Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Fourteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Rhythm Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $78.07.

Get Our Latest Report on RYTM

Rhythm Pharmaceuticals Price Performance

NASDAQ:RYTM traded up $0.62 during trading hours on Monday, reaching $66.39. The company's stock had a trading volume of 821,801 shares, compared to its average volume of 559,165. The company has a market cap of $4.22 billion, a price-to-earnings ratio of -23.63 and a beta of 2.26. Rhythm Pharmaceuticals has a one year low of $40.61 and a one year high of $69.89. The business's 50-day moving average is $62.86 and its 200-day moving average is $58.50.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The company had revenue of $37.72 million for the quarter, compared to the consensus estimate of $40.43 million. During the same quarter last year, the company posted ($2.35) EPS. The business's revenue was up 25.9% compared to the same quarter last year. On average, sell-side analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 2,069 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $67.19, for a total transaction of $139,016.11. Following the sale, the chief accounting officer directly owned 1,889 shares in the company, valued at approximately $126,921.91. The trade was a 52.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alastair Garfield sold 1,319 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $64.81, for a total transaction of $85,484.39. Following the sale, the insider owned 3,126 shares in the company, valued at approximately $202,596.06. This trade represents a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,705 shares of company stock worth $3,930,651. 6.10% of the stock is owned by company insiders.

Institutional Trading of Rhythm Pharmaceuticals

A number of large investors have recently bought and sold shares of RYTM. Westfield Capital Management Co. LP bought a new position in shares of Rhythm Pharmaceuticals during the first quarter valued at $71,038,000. Janus Henderson Group PLC lifted its holdings in Rhythm Pharmaceuticals by 103.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock valued at $68,309,000 after purchasing an additional 621,432 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Rhythm Pharmaceuticals by 75.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,199,053 shares of the company's stock valued at $63,515,000 after buying an additional 513,901 shares in the last quarter. Marshall Wace LLP boosted its position in Rhythm Pharmaceuticals by 70.4% in the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock valued at $38,783,000 after buying an additional 286,188 shares in the last quarter. Finally, Siren L.L.C. bought a new stake in Rhythm Pharmaceuticals during the first quarter worth about $14,701,000.

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

See Also

Analyst Recommendations for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.

While Rhythm Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines